BDSX Stock Forecast 2025-2026
Distance to BDSX Price Targets
BDSX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Biodesix (BDSX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BDSX and similar high-potential opportunities.
Latest BDSX Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, BDSX has a bullish consensus with a median price target of $3.00 (ranging from $3.00 to $3.50). Currently trading at $0.80, the median forecast implies a 276.0% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kyle Mikson at Canaccord Genuity, projecting a 338.7% upside. Conversely, the most conservative target is provided by Sung Ji Nam at Scotiabank, suggesting a 276.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BDSX Analyst Ratings
BDSX Price Target Range
Latest BDSX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BDSX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 16, 2024 | Scotiabank | Sung Ji Nam | Sector Outperform | Initiates | $3.00 |
| Jul 26, 2024 | Craig-Hallum | Bill Bonello | Buy | Initiates | $3.00 |
| May 13, 2024 | TD Cowen | Dan Brennan | Buy | Initiates | $2.80 |
| May 3, 2024 | Lake Street | Buy | Initiates | $3.00 | |
| Mar 4, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Reiterates | $3.50 |
| Dec 7, 2023 | Canaccord Genuity | Kyle Mikson | Buy | Reiterates | $3.50 |
| May 12, 2022 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $5.00 |
| Apr 20, 2022 | Cowen & Co. | Outperform | Initiates | $0.00 | |
| Nov 17, 2021 | Morgan Stanley | Tejas Savant | Equal-Weight | Downgrade | $11.00 |
| May 12, 2021 | Morgan Stanley | Overweight | Maintains | $23.00 | |
| Mar 18, 2021 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $25.00 |
| Feb 2, 2021 | Canaccord Genuity | Max Masucci | Buy | Maintains | $31.00 |
| Nov 23, 2020 | William Blair | Outperform | Initiates | $0.00 | |
| Nov 23, 2020 | Morgan Stanley | Overweight | Initiates | $0.00 | |
| Nov 23, 2020 | BTIG | Buy | Initiates | $0.00 |
Biodesix Inc. (BDSX) Competitors
The following stocks are similar to Biodesix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biodesix Inc. (BDSX) Financial Data
Biodesix Inc. has a market capitalization of $121.23M with a P/E ratio of 0.0x. The company generates $71.32M in trailing twelve-month revenue with a -60.2% profit margin.
Revenue growth is +39.3% quarter-over-quarter, while maintaining an operating margin of -32.0% and return on equity of -337.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Biodesix Inc. (BDSX) Business Model
About Biodesix Inc.
Provides innovative blood-based diagnostics for lung cancer.
The company generates revenue by offering proprietary diagnostic tests that assist in the detection, diagnosis, and monitoring of lung cancer. These tests are primarily aimed at healthcare providers and patients, enhancing clinical decision-making and optimizing treatment strategies in oncology.
Biodesix Inc. operates within the biotechnology sector, focusing on personalized medicine through non-invasive testing. Its contributions play a significant role in the shift towards precision healthcare, aiming to improve patient outcomes and quality of life by supporting tailored therapies and advancing cancer treatment development.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
273
CEO
Mr. Scott Hutton
Country
United States
IPO Year
2020
Website
www.biodesix.comBiodesix Inc. (BDSX) Latest News & Analysis
Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings potential, which may lead to a rise in the stock price.
Biodesix's upgrade to a Zacks Rank #2 signals positive earnings expectations, potentially boosting investor confidence and driving the stock price up.
Biodesix, Inc. (NASDAQ:BDSX) will hold its Q4 2024 Earnings Conference Call on March 3, 2025, at 4:30 PM ET, featuring executives including CEO Scott Hutton and CFO Robin Harper Cowie.
The earnings call provides insights into Biodesix's financial performance, future outlook, and strategic direction, influencing investor sentiment and stock valuation.
FY2024 total revenue is $71.3M, a 45% increase from FY2023, with gross margins at 78%. Guidance for FY2025 revenue is $92-95M. Conference call at 4:30 p.m. ET today.
Strong revenue growth and improved gross margins indicate robust business performance. FY2025 guidance suggests continued momentum, which could positively impact stock valuations and investor sentiment.
Biodesix, Inc. (Nasdaq: BDSX) will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, with CEO Scott Hutton and CFO Robin Cowie hosting investor meetings.
Biodesix's leadership participation at a major healthcare conference signals potential growth opportunities and investor engagement, which may influence stock performance and market perception.
Biodesix, Inc. (Nasdaq: BDSX) will release its financial results for Q4 and full year 2024 on March 3, 2025, after market close.
Biodesix's upcoming financial results may influence stock performance, revealing insights into growth, profitability, and market position, impacting investor sentiment and decisions.
Full-year revenue is estimated at $71.3 million, marking a 45% increase.
A 45% revenue increase to $71.3 million signals strong company growth, potentially boosting investor confidence and stock value.
Frequently Asked Questions About BDSX Stock
What is Biodesix Inc.'s (BDSX) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Biodesix Inc. (BDSX) has a median price target of $3.00. The highest price target is $3.50 and the lowest is $3.00.
Is BDSX stock a good investment in 2025?
According to current analyst ratings, BDSX has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BDSX stock?
Wall Street analysts predict BDSX stock could reach $3.00 in the next 12 months. This represents a 276.0% increase from the current price of $0.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biodesix Inc.'s business model?
The company generates revenue by offering proprietary diagnostic tests that assist in the detection, diagnosis, and monitoring of lung cancer. These tests are primarily aimed at healthcare providers and patients, enhancing clinical decision-making and optimizing treatment strategies in oncology.
What is the highest forecasted price for BDSX Biodesix Inc.?
The highest price target for BDSX is $3.50 from Kyle Mikson at Canaccord Genuity, which represents a 338.7% increase from the current price of $0.80.
What is the lowest forecasted price for BDSX Biodesix Inc.?
The lowest price target for BDSX is $3.00 from Sung Ji Nam at Scotiabank, which represents a 276.0% increase from the current price of $0.80.
What is the overall BDSX consensus from analysts for Biodesix Inc.?
The overall analyst consensus for BDSX is bullish. Out of 7 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are BDSX stock price projections?
Stock price projections, including those for Biodesix Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
